Fig. 5
Reduced airway EPX release in eoCRE/V7 mice following OVA-induced allergic airway inflammation. a Schematic timeline of the acute OVA sensitization and challenge procedure used to induce allergic airway inflammation. On day 28, multiple endpoint pathologies were assessed. b Total BAL cellularity was compared in saline- and OVA-treated control and eoCRE/V7 mice, together with (c) BAL cell differentials on day 28 of OVA treatment. BAL levels of (d) EPX and (e) MBP from saline- and OVA-treated control and eoCRE/V7 mice. Values are mean ± SEM. For experiments shown in Fig. 5b and c, n = 5–6. In Fig. 5d and e, n = 7–10 BAL samples were measured from individual mice (each marker represents a single mouse). *p < 0.05, ***p < 0.001, using one-way ANOVA with Tukey’s post hoc analysis
